Tulissin 100 mg/ml - Solution for injection (cattle, pigs, sheep)

Authorised

- Tulathromycin

Product identification

Medicine name:
Tulissin 100 mg/ml - Solution for injection (cattle, pigs, sheep)

Active substance:
Tulathromycin

Target species:
Cattle
Sheep
Pig

Route of administration:
Intramuscular use
Subcutaneous use

Product details

Active substance and strength:
Tulathromycin
100.00 milligram(s) / 1.00 Vial

Pharmaceutical form:
Solution for injection

Withdrawal period by route of administration:

Intramuscular use:

- **Cattle**
  - Meat and offal. 22 day — 22 days
- **Sheep**
  - Meat and offal. 16 day — 16 days
- **Pig**
  - Meat and offal. 13 day — 13 days

Subcutaneous use:

- **Cattle**
  - Meat and offal. 22 day — 22 days
- **Sheep**
  - Meat and offal. 16 day — 16 days
- **Pig**
  - Meat and offal. 13 day — 13 days

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QJ01FA94

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:

Austria , Belgium , Croatia , Czechia , Denmark , Estonia , Finland , France , Greece , Hungary , Ireland , Italy , Latvia , Lithuania , Poland , Portugal , Romania , Slovakia , Slovenia , United Kingdom (Northern Ireland)

Package description:

Packaging:Vial (glass), Package_size:1 vial, Content:20 ml

Packaging:Vial (glass), Package_size:1 vial, Content:50 ml

Packaging:Vial (glass), Package_size:1 vial, Content:250 ml

Packaging:Vial (glass), Package_size:1 vial, Content:100 ml

Packaging:Vial (glass) with protective sleeve, Package_size:1 vial, Content:250 ml

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Virbac

Marketing authorisation date:

24/04/2020

Manufacturing sites for batch release:

Fareva Amboise

Virbac

Responsible authority:

European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
24/04/2020

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 15/01/2026
Download

ema-puar-tulissin-v-5073-par-en.pdf